Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brundin, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brundin, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 125, No. 10, 2149-2151, October 2002
© 2002 Oxford University Press

Editorial

GDNF treatment in Parkinson’s disease: time for controlled clinical trials?

Patrik Brundin

Department of Physiological Sciences Lund University, Sweden

The first 150 words of the full text of this article appear below.

Restorative treatments for brain disorders are rare. In neuroscience research, it is not uncommon to suggest that experimental treatment strategies may have great clinical potential. The rescue or regeneration of a few cultured neurones may be sufficient to entice such optimism. However, the path to a new clinical therapy is typically painstakingly long and difficult to navigate. In our minds, we would like it always to be a straight path starting with tests in cell models and rodents providing us with mechanisms of action and leading to trials in non-human primates. Then open-label tests can be performed in small patient groups and eventually large controlled clinical trials are conducted. In reality, however, the path may be tortuous, filled with detours that set the field back, as well as shortcuts and parallel tracks that yield different strategies which develop at their own speed. The development of glial cell line-derived neurotrophic factor . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
D. N. Hovland Jr., R. B. Boyd, M. T. Butt, J. A. Engelhardt, M. S. Moxness, M. H. Ma, M. G. Emery, N. B. Ernst, R. P. Reed, J. R. Zeller, et al.
Reprint: Six-Month Continuous Intraputamenal Infusion Toxicity Study of Recombinant Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) in Rhesus Monkeys
Toxicol Pathol, December 1, 2007; 35(7): 1013 - 1029.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
D. N. Hovland Jr., R. B. Boyd, M. T. Butt, J. A. Engelhardt, M. S. Moxness, M. H. Ma, M. G. Emery, N. B. Ernst, R. P. Reed, J. R. Zeller, et al.
Six-Month Continuous Intraputamenal Infusion Toxicity Study of Recombinant Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) in Rhesus Monkeys
Toxicol Pathol, August 1, 2007; 35(5): 676 - 692.
[Abstract] [Full Text] [PDF]